title: Levocetirizine improves health-related quality of life and health status in persistent allergic rhinitis.
abstract: BACKGROUND
  Allergic rhinitis is a chronic respiratory disorder with a detrimental impact on health-related quality of life (HRQOL) and health status. Enhancement and maintenance of patient function and well-being are therefore considered as essential.
  
  
  OBJECTIVE
  To determine whether long-term treatment with levocetirizine 5mg improves HRQOL and health status in persistent allergic rhinitis (PER) patients assessed with RQLQ and SF-36 scales over a 6-month period.
  
  
  METHODS
  The Xyzal in PER Trial (XPERT) was a multi-center, double-blind, parallel-group study. A total of 551 patients were randomized to receive levocetirizine 5mg or placebo once daily for 6 months and assessed for symptoms, HRQOL (Rhinoconjunctivitis Quality of Life Questionnaire: RQLQ) and health status (SF-36). Sensitivity of the RQLQ and SF-36 to disease severity was tested to ensure their suitability for use in PER patients. Treatment effect was assessed by means of repeated measures analyses.
  
  
  RESULTS
  Over the 6-month treatment period, levocetirizine showed statistically significant improvements over placebo in HRQOL (P < 0.001 for all RQLQ domains and overall scores) and health status (P < or = 0.004 for SF-36 physical and mental summary scores; P < 0.05 for all SF-36 scales). The relative improvement of levocetirizine over placebo exceeded the predefined clinically meaningful threshold of 30% for all RQLQ scores and the improvement from baseline was 3 times the established MID for RQLQ.
  
  
  CONCLUSIONS
  The RQLQ and SF-36 could be used to measure HRQOL and health status in PER patients. Long-term treatment with levocetirizine provides sustained improvement of HRQOL and reduces disease burden in PER patients.
authors.affiliation: Allergy & Respiratory Diseases Clinic, DIMI, Genoa University, Pad. Maragliano, L.go R. Benzi 10, 16132 Genoa, Italy. canonica@unige.it
authors.forename: G
authors.initials: G
authors.lastname: Walter Canonica
authors.forename: Jean
authors.initials: J
authors.lastname: Bousquet
authors.forename: Geneviève
authors.initials: G
authors.lastname: Van Hammée
authors.forename: Claus
authors.initials: C
authors.lastname: Bachert
authors.forename: Stephen R
authors.initials: SR
authors.lastname: Durham
authors.forename: Ludger
authors.initials: L
authors.lastname: Klimek
authors.forename: Joaquim
authors.initials: J
authors.lastname: Mullol
authors.forename: Paul B
authors.initials: PB
authors.lastname: Van Cauwenberge
mesh_terms: D017332:Cetirizine / Q000627:therapeutic use*; D004311:Double-Blind Method; D006304:Health Status; D039563:Histamine H1 Antagonists, Non-Sedating / Q000627:therapeutic use*; D006801:Humans; D010879:Piperazines / Q000627:therapeutic use*; D011788:Quality of Life; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D039563:Histamine H1 Antagonists, Non-Sedating; D010879:Piperazines; C472067:levocetirizine; D017332:Cetirizine